February 1, 2023 – Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, has expanded its product portfolio with the introduction of a disposable pen injector. Ideally suited for high-volume manufacturing, Phillips-Medisize offers pharmaceutical companies a familiar highly competitive pen injector to facilitate faster, more efficient and cost-effective market entry.
Phillips-Medisize has expanded its platform portfolio with a new, compact pen injector featuring flexible design and customizable dosing ideally suited for high-volume manufacturing and faster rollout of novel and generic drug treatments.
The pen injector has been designed to match user expectations and experiences with familiar disposable pen products, yet is noticeably smaller than most comparable offerings in the market. In addition to its compact form factor, this pen injector features a flexible design with customizable dosing as well as push-button colors to signal different dosing and drug requirements for multiple therapies, including diabetes, fertility, growth hormones, obesity and osteoporosis.
Sample devices are available to support technical evaluation and human factors studies, with clinical devices scheduled for the end of 2023. As a result, this pen injector is strongly positioned to help drug-delivery companies respond to the rapidly rising, billion-unit-plus disposable pen injector market while reducing commercialization costs and risks.
As a global leader of integrated, end-to-end solutions, Phillips-Medisize produces nearly 400 million medical devices on behalf of its customers each year. Decades of trusted collaborations with pharmaceutical companies have resulted in the production of off-the-shelf device platforms, along with the design, development and manufacturing of complex or specialized devices and advanced solutions with embedded connectivity.
The Pen Injector Platform joins Phillips-Medisize’s Aria Smart Autoinjector, which was introduced in May 2021 to meet rising demands for innovation, differentiation and sustainability in the digital drug-delivery device market. Through the introduction of the pen injector, Phillips-Medisize can offer Biopharma companies greater choice across the two largest injector market segments, providing highly competitive products combined with leading contract manufacturing and development capability.